The transaction also includes the NovaDel patents and trademarks covered by NovaDel’s license agreement with Akrimax Pharmaceuticals, LLC for US rights to NitroMist® as well as the license agreement itself. The consideration for the sale was the assumption of the FDA fees, interest and penalties relating to NitroMist® owed by NovaDel up to the closing of the transaction. These fees, interest and penalties approximate $2,400,000.
Help employers find you! Check out all the jobs and post your resume.
